Equities Analysts Offer Predictions for STOK Q1 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a note issued to investors on Wednesday, February 19th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.58) for the quarter, down from their prior estimate of ($0.56). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($3.06) EPS, FY2027 earnings at ($3.16) EPS, FY2028 earnings at ($2.71) EPS and FY2029 earnings at ($2.03) EPS.

STOK has been the subject of a number of other reports. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday. HC Wainwright raised their price target on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday. Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Trading Down 4.7 %

Shares of Stoke Therapeutics stock opened at $8.33 on Friday. The business has a 50-day moving average price of $10.55 and a two-hundred day moving average price of $12.29. Stoke Therapeutics has a 1-year low of $5.21 and a 1-year high of $17.58. The company has a market cap of $441.24 million, a P/E ratio of -3.97 and a beta of 0.95.

Insider Activity at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 9,696 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the transaction, the general counsel now owns 35,142 shares of the company’s stock, valued at approximately $449,114.76. The trade was a 21.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Barry Ticho sold 13,945 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10. Following the sale, the insider now directly owns 47,332 shares in the company, valued at $604,902.96. This trade represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,849 shares of company stock worth $809,421. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Toronto Dominion Bank purchased a new stake in shares of Stoke Therapeutics in the fourth quarter worth $35,001,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company’s stock worth $1,053,000 after acquiring an additional 52,813 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Stoke Therapeutics by 6.7% in the 4th quarter. Squarepoint Ops LLC now owns 120,242 shares of the company’s stock valued at $1,326,000 after acquiring an additional 7,575 shares in the last quarter. Tang Capital Management LLC bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $3,309,000. Finally, RTW Investments LP grew its holdings in shares of Stoke Therapeutics by 10.1% during the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after purchasing an additional 471,240 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.